Elamipretide Improves Mitochondrial Function in the Failing Human Heart

Area of Science:

• Cardiology
• Mitochondrial Biology
• Pharmacology

Background:

• Mitochondrial dysfunction is a key feature of heart failure (HF).
• Specific alterations in mitochondrial complexes and supercomplexes contribute to HF pathophysiology.
• Targeting mitochondria offers a potential therapeutic strategy for HF.

Purpose of the Study:

• To investigate the effects of elamipretide, a mitochondrial-targeted therapeutic, on mitochondrial and supercomplex function in failing human hearts.
• To assess elamipretide's impact on mitochondrial oxygen consumption and specific enzyme activities ex vivo.

Main Methods:

• Ex vivo treatment of human ventricular tissue (failing and nonfailing) with elamipretide.
• Measurement of mitochondrial oxygen flux.
• Assay of Complex I and Complex IV activities.
• Analysis of mitochondrial supercomplex assembly and activity.

Main Results:

• Mitochondrial function was demonstrably impaired in failing human hearts.
• Elamipretide treatment significantly enhanced mitochondrial oxygen flux.
• Complex I and Complex IV activities, including supercomplex-associated Complex IV, were improved by elamipretide.
• Elamipretide administration led to a significant improvement in overall mitochondrial function in failing hearts.

Conclusions:

• Elamipretide effectively improves mitochondrial function in failing human hearts ex vivo.
• Targeting mitochondrial pathways with agents like elamipretide represents a promising therapeutic avenue for heart failure.
• Further investigation into elamipretide's clinical efficacy in heart failure is warranted.